Abstract
Carvedilol is a nonselective β-blocker with α1-adrenergic blocking and antioxidant properties. A number of preclinical experiments and clinical trials have demonstrated that carvedilol provides prominent benefit in heart failure. However, less research has been done in the area of animal models of viral myocarditis. This paper reviews the use of carvedilol in animal models of viral myocarditis. The experimental evidence strongly suggests that carvedilol, but not metoprolol (a selective β1-adrenergic blocking agent), protects against viral myocarditis and the superior cardioprotection effect of carvedilol to metoprolol may be due to its upregulating the production of antiinflammatory cytokines, downregulating the production of proinflammatory cytokines, antioxidative effects, the suppression of matrix metalloproteinases production, and positive hemodynamic effects.
Keywords: Carvedilol, viral myocarditis, cytokines, antioxidants, hemodynamics, nonselective -blocker, heart failure, metoprolol, matrix metalloproteinases production, viral injury
Current Pharmaceutical Design
Title:The Mechanism of Carvedilol in Experimental Viral Myocarditis
Volume: 18 Issue: 12
Author(s): Li Yue-Chun, Ge Li-Sha, Guan Xue-Qiang, Lin Jia-Feng
Affiliation:
Keywords: Carvedilol, viral myocarditis, cytokines, antioxidants, hemodynamics, nonselective -blocker, heart failure, metoprolol, matrix metalloproteinases production, viral injury
Abstract: Carvedilol is a nonselective β-blocker with α1-adrenergic blocking and antioxidant properties. A number of preclinical experiments and clinical trials have demonstrated that carvedilol provides prominent benefit in heart failure. However, less research has been done in the area of animal models of viral myocarditis. This paper reviews the use of carvedilol in animal models of viral myocarditis. The experimental evidence strongly suggests that carvedilol, but not metoprolol (a selective β1-adrenergic blocking agent), protects against viral myocarditis and the superior cardioprotection effect of carvedilol to metoprolol may be due to its upregulating the production of antiinflammatory cytokines, downregulating the production of proinflammatory cytokines, antioxidative effects, the suppression of matrix metalloproteinases production, and positive hemodynamic effects.
Export Options
About this article
Cite this article as:
Li Yue-Chun, Ge Li-Sha, Guan Xue-Qiang, Lin Jia-Feng , The Mechanism of Carvedilol in Experimental Viral Myocarditis , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958530
DOI https://dx.doi.org/10.2174/138161212799958530 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Oxidative Stress, Antioxidants, and Endothelial Function
Current Medicinal Chemistry Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Current Hypertension Reviews Molecular Treatment of Different Breast Cancers
Anti-Cancer Agents in Medicinal Chemistry Cardiac Tissue Engineering
Recent Patents on Regenerative Medicine Folding, Assembly, and Stability of Transmembrane Cytochromes
Current Chemical Biology Inflammatory Biomarkers in Atrial Fibrillation
Current Medicinal Chemistry Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Future Challenges for Microsomal Transport Protein Inhibitors
Current Vascular Pharmacology Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents
Current Drug Therapy Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Current Pharmaceutical Design Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Potential Applications of Hydrogen Sulfide-Induced Suspended Animation
Current Medicinal Chemistry Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Efficacy and Cardiovascular Safety of Meglitinides
Current Drug Safety Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Modulation of Cardiovascular Function by Adipokines
Cardiovascular & Hematological Disorders-Drug Targets